Targeting HOX-PBX interactions causes death in oral potentially malignant and squamous carcinoma cells but not normal oral keratinocytes by Platais, C. et al.
This is a repository copy of Targeting HOX-PBX interactions causes death in oral 
potentially malignant and squamous carcinoma cells but not normal oral keratinocytes.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/134516/
Version: Published Version
Article:
Platais, C., Radhakrishnan, R., Ebensberger, S.N. et al. (3 more authors) (2018) Targeting 
HOX-PBX interactions causes death in oral potentially malignant and squamous 
carcinoma cells but not normal oral keratinocytes. BMC Cancer, 18. 723. ISSN 1471-2407 
https://doi.org/10.1186/s12885-018-4622-0
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE Open Access
Targeting HOX-PBX interactions causes
death in oral potentially malignant and
squamous carcinoma cells but not normal
oral keratinocytes
Christopher Platais1, Raghu Radhakrishnan1, Sven Niklander Ebensberger1,2, Richard Morgan3,
Daniel W. Lambert1 and Keith D. Hunter1,4*
Abstract
Background: High HOX gene expression has been described in many cancers, including oral squamous cell
carcinoma and the functional roles of these genes are gradually being understood. The pattern of overexpression
suggests that inhibition may be useful therapeutically. Inhibition of HOX protein binding to PBX cofactors by the
use of synthetic peptides, such as HXR9, results in apoptosis in multiple cancers.
Methods: Activity of the HOX-PBX inhibiting peptide HXR9 was tested in immortalised normal oral (NOK),
potentially-malignant (PMOL) and squamous cell carcinoma (OSCC) cells, compared to the inactive peptide
CXR9. Cytotoxicity was assessed by LDH assay. Expression of PBX1/2 and c-Fos was assessed by qPCR and
western blotting. Apoptosis was assessed by Annexin-V assay.
Results: PMOL and OSCC cells expressed PBX1/2. HOX-PBX inhibition by HXR9 caused death of PMOL and
OSCC cells, but not NOKs. HXR9 treatment resulted in apoptosis and increased expression of c-Fos in some
cells, whereas CXR9 did not. A correlation was observed between HOX expression and resistance to HXR9.
Conclusion: Inhibition of HOX-PBX interactions causes selective apoptosis of OSCC/PMOL, indicating selective
toxicity that may be useful clinically.
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Background
The HOX proteins are an important family of transcrip-
tion factors that control a wide array of functions in em-
bryogenesis and the maintenance of normal tissue [1, 2].
Their dysregulation has been implicated in the develop-
ment of a variety of cancers [3–5], including oral squa-
mous cell carcinoma (OSCC) and we have shown that
these changes also occur in cells from potentially malig-
nant oral lesions (PMOLs) [6, 7]. Recent studies have
highlighted the therapeutic potential of inhibiting the
interaction between HOX proteins and a common group
of co-factors, the PBX proteins, using the synthetic pep-
tide HXR9 [8]. The consistent phenotypic effect reported
on inhibition of HOX-PBX interactions is induction of
apoptosis that has been reported in a number of malig-
nant cell types [9–13]. This has been associated with up-
regulation of c-Fos protein, which, whilst most often
regarded as a proto-oncogene, may in some circum-
stances be pro-apoptotic [14].
This project aimed to determine whether targeting
HOX-PBX interactions has therapeutic potential in
OSCCs and PMOLs by assessing the expression of PBX1
and PBX2 in PMOL and OSCC cells and investigating
the effect of HOX-PBX inhibition on these cells and in
normal oral keratinocytes.
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Methods
Cell culture
Two immortalised normal oral keratinocyte (iNOK:
FNB6TERT and OKF4), two PMOL (D19 and D35)
and four OSCC (B16, B22, B56, T5) cell lines were
used in this project, as outlined in Table 1. Cell lines
FNB6TERT, D19, D35, B16, B22, B56 and T5 were sup-
plied from the Beatson Institute of Cancer Research cell
culture collection and OKF4 was supplied by Dr. J Rhein-
wald (Harvard University, Boston). These cells have been
previously extensively characterised [15] and were cul-
tured to a maximum of 70% confluence in keratinocyte
growth medium (KGM). Two PMOL (D19, D35) and two
OSCC (B16, B22) cell lines were used for the peptide
treatment experiments.
RNA isolation and qRT-PCR
Expression of c-Fos and the HOX cofactors PBX1 and
PBX2 was assessed using RNA extracted from cells with
the Isolate II RNA Mini Kit (Bioline, UK), following the
manufacturer’s instructions. Following cDNA gener-
ation, the transcript levels of PBX1 and PBX2 were
measured using SYBR Green qPCR (Primer sequences:
PBX1 forward: 5’ ATTGCAATCCCCCTGCCTTC 3′
reverse: 5’ TTCAGTCCGGTCTCCTTTGC 3′; PBX2
forward: 5’ GATGTACAGCCCACGGGAAA 3′ reverse:
5’ CCGTTGGGGATGTCACTGAA 3′) on a 7900HT Fast
Real-Time PCR System (Life Technologies, UK). The ex-
pression of c-Fos was assessed using SYBR Green qPCR
(Primer sequences - forward: 5’ CCAACCTGCTGAAG
GAGAAG 3′ and reverse: 5’ GCTGCTGATGCTCTTG
ACAG 3′). Data is presented relative to expression of U6.
Published expression data for all 39 HOX genes was used
to assess possible relationships between peptide sensitivity
and HOX gene expression [6].
Peptide treatment
The HOX-PBX interfering peptide HXR9 and control
peptide (CXR9) were custom synthesised by Bio-Synthesis
Inc., (Lewisville, Tx, USA), D-isomer to > 90% purity.
HXR9: WYPWMKKHHRRRRRRRRR (2700.06 Da),
CXR9: WYPAMKKHHRRRRRRRRR (differs from HXR9
by a single amino acid [16], 2604.14 Da). The EC50 of
HXR9 and CXR9 was calculated for FNB6TERT, OKF4,
D19, D35, B16 and B22 cells using increasing doses of
peptide (0.5, 5, 12.5, 25, 50, 75 and 100 μM).
LDH assay
Cell death was assessed using a lactate dehydrogenase
(LDH) cytotoxicity assay (Promega, UK) after 2 h 45 min
of peptide treatment, according to the manufacturer’s
instructions.
Annexin–V assay
The induction of apoptosis at EC50 was investigated
using the Annexin-V FITC flow cytometry assay (Trevigen,
UK) according to the manufacturer’s instructions,
using a LSR II flow cytometer (BD Biosciences, San
Jose, CA, USA). Gating was applied to the scatter
plots to identify cells as viable, early apoptotic, late apop-
totic or necrotic. The position of the gate and the quad-
rants were kept constant between plots of the same cell
type, so that the proportions could be compared between
treatments.
Western blot
Western blotting of whole cell lysate (generated using
RIPA buffer) was used to assess expression of PBX1 and
PBX2 protein. The antibodies used were anti-PBX1:
Abcam ab154285 at 1:500, anti-PBX2: Abcam ab55498
at 1:500, and anti-c-Fos (Abcam; ab209794 at 1:100).
HeLa whole cell lysate was used as a positive control.
Statistical methods
Statistical analysis was conducted using ANOVA to as-
sess differences between the expression of these markers
in the cell lines tested. The correlation between HOX
gene expression and PBX expression was assessed by
calculating the Spearman Correlation coefficient. Dif-
ferences were considered significant if p < 0.05.
Table 1 Clinical details relating to the PMOL and OSCC cell lines used in the project. All patients (except B22, unknown status), were
smokers. The primary site for B22 was the lateral tongue
Cell line Age/Gender Site Histology Stage (pTNM)
B16 48 M Lateral tongue SCC T2 N0 M0
B22 88 M Lymph node metastasis SCC T4 N3 M0
B56 59 F Lateral tongue SCC T4 N1 M0
T5 59 F Buccal mucosa SCC T2 N2 M0
D19 53 M Lateral tongue leukoplakia Severe dysplasia N/A
D35 68 M Lateral tongue erythro-leukoplakia Severe dysplasia N/A
SCC Squamous cell carcinoma
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Results
PMOL and OSCC cells express PBX1 and PBX2
Investigation of PBX1 and PBX2 mRNA and protein
expression in PMOL and OSSC cells demonstrated
that all cell lines express both PBX1 and PBX2
(Fig. 1a and b). The expression is variable and the
relative expression of PBX2 is higher than PBX1.
Expression of PBX1 is significantly higher in D35
than in the other cell lines (p < 0.05). The expression
of PBX proteins largely corresponds to that of the
mRNA expression.
Treatment with HXR9, but not CXR9, results in death of
PMOL and OSCC cells
HXR9 causes dose dependent death of both PMOL
and OSCC cells, whilst iNOKs are insensitive in the
concentration range used (Fig. 2a). The control pep-
tide CXR9 has no effect on cell viability in the same
concentration range. The EC50 of T5 and B56 is
48 μM and 151 μM SCC: squamous cell carcinomar-
espectively (data not shown). The sensitivity of the
OSCC and PMOL cells varies, with D35 most sensi-
tive and B56 relatively insensitive. Correlation of
EC50 values with mRNA expression of PBX1, PBX2
or expression of HOXA, HOXB, HOXC and HOXD
demonstrated that the EC50 was positively correlated
with the mean expression of all HOX 39 genes and
gene expression of each individual HOX cluster (Fig. 2b).
There was no relationship between PBX1 or PBX2 expres-
sion and EC50.
HXR9 induces apoptosis and increased expression of
cFOS
Despite variations in the proportion of apoptosis
cells in the untreated cultures, assessment of induc-
tion of apoptosis demonstrated that treatment with
HXR9 resulted in a significantly higher proportion of
cells in late apoptosis when compared to those
treated with CXR9 (Fig. 3a). Expression of c-Fos
mRNA increased after treatment with HXR9 in all
cells to a far greater extent than in CXR9 treated
cells (Fig. 3b). However, expression of c-Fos protein
only increased in B16 and D19 cells, albeit these
cells also showed the largest increase in mRNA ex-
pression (Fig. 3c).
Fig. 1 Expression of PBX1 and PBX2 in a panel of PMOL (D19 and D35) and OSCC (B16, B22, B56 and T5) cell lines. Panel a: qPCR data,
mean±SEM from three individual experiments. Panel b: western blot, with β-actin as a loading control
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Discussion
Identification of effective molecularly based thera-
peutics is vital if similar breakthroughs are to be
made in the treatment of OSCC as in other solid tu-
mours such as breast cancer. The observation that
dysregulation of HOX gene expression occurs early
in the pathogenesis of OSCC makes this family of
transcription factors an attractive therapeutic target
[7]. The main challenge in targeting HOX genes is
their functional redundancy and the relatively con-
served DNA binding site, thus specifically targeting
individual HOX genes is unlikely to be feasible. The
discovery that many HOX genes (particularly paralo-
gous groups 1–8) require co-factor binding for stable
interaction with DNA opens the potential for inter-
fering with this interaction pharmaceutically using
the HXR9 peptide. The effects of HXR9 have been
demonstrated in a number of solid malignancies in
vitro and in vivo [9, 11, 12, 17]. In this paper, we
demonstrate the sensitivity of oral cancer cells to
this agent, similar to that reported for other cancers,
but in addition, we demonstrate similar effects on
cells derived from potentially malignant oral lesions
and the lack of effect on normal oral keratinocytes.
This measure of selectivity was not seen on compari-
son of breast cancer cell lines with MCF10A cells
where the sensitivity of three of the five cell lines
tested was no different from the non-malignant
MCF10A cells [11].
The data also suggests that HOX-PBX inhibition
may be an effective strategy to prevent the develop-
ment of OSCC due to its selective toxicity in PMOL
cells. This may have particular benefit in the treat-
ment of large PMOLs, which are not amenable to
surgery, and for the prevention of subsequent malig-
nancies in patients who have already developed an
Fig. 2 Panel a: Relative viability of PMOL, OSCC cells and iNOKs (FNB6 and OKF4) after treatment with increasing doses of HXR9 and control
peptide (CXR9; Mean±SEM from three independent experiments). The calculated EC50 stated for each cell line. Panel b: Correlation of expression
of EC50 with mean expression of genes from all four HOX clusters (left panel; Spearman Coefficient 0.943, p < 0.01) and HOXA cluster genes
(right panel: Spearman Coefficient 0.943, p < 0.01)
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upper aero-digestive tract malignancy. These are sig-
nificant clinical issues in the management of patients
with PMOLs and OSCC.
The sensitivity of PMOL and OSCC cells is corre-
lated with HOX gene expression overall and the me-
dian expression of the individual clusters, most
particularly HOXA cluster genes (paralogues 1–8).
Despite modest variation in expression of PBX1 and
PBX2, there is no relationship between this and the
EC50 of HXR9 in these cells. Presumably, this indi-
cates that PBX co-factors are present in excess and
as such, it is the aberrant expression of HOX genes
in OSCC pathogenesis that confers the specificity.
There was no effect on NOKs at the concentrations
tested.
The mechanism of cell death induced by HXR9
has been demonstrated to be apoptosis in other
solid malignancies [9, 11, 12, 17]. Similarly, we
found that treatment of PMOL and OSCC cells with
HXR9 resulted in induction of apoptosis with a sig-
nificant increase in the number of cells in late apop-
tosis (Fig. 3).
HXR9 also increased c-Fos expression, which has
been reported in other tumours, such as melanoma
and prostate cancer [8, 10] (Fig. 4). Whilst mRNA ex-
pression increased markedly after HXR9 treatment, the
Fig. 3 Panel a: Induction of apoptosis (assessed by translocation of phosphatidylserine by Annexin-V) in untreated cells and on treatment of cells
with CXR9 and HXR9 at EC50 for 2 h 45 min. Blue = viable, red = early apoptotic, green = late apoptotic and purple = dead. Comparisons are of %
of late apoptotic cells: Mean±SEM from three individual experiments. *p < 0.05, **p < 0.01. Panel b: Exemplar scatter plots for the PMOL cell line
D19 cells: untreated, HXR9 treated and control (CXR9) treated. Each quadrant represents a cell status; clockwise from upper left: dead, late
apoptotic, early apoptotic and viable
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increase in the expression of c-Fos protein is less con-
sistent. Both the mRNA transcript and protein prod-
ucts are short lived and undergo rapid degradation.
This indicates that further studies are required on the
dynamics of c-Fos expression in these cells after treat-
ment with HXR9.
Conclusion
These data demonstrate the therapeutic potential of
HOX-PBX inhibitors not only in OSCC, but also in
PMOLs, suggesting a wide range of possible thera-
peutic uses. This is a specific effect on cells with dys-
regulated HOX gene expression and iNOKs are not
affected.
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